Please assess the completion status of the following clinical trial:

Trial Title: Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to provide written informed consent in a time window 1 to 3 days after successful PCI;~2. Male or female, age ≥ 75 years at screening;~3. ACS at the time of the index hospitalization;~4. Use of a loading dose of 180 mg of ticagrelor administered after diagnosis of ACS or after PCI;~5. Use of a maintenance dose of 90 mg twice daily of ticagrelor of at least 48 hours after the loading dose;~6. Successful PCI (Thrombolysis In Myocardial Infarction \[TIMI\] flow 3 and residual coronary stenosis \<30%) for non-ST-segment elevation ACS or ST-segment elevation myocardial infarction~Exclusion Criteria:~1. Use of glycoprotein IIb/IIIa receptor inhibitors;~2. Need for chronic oral anticoagulant therapy;~3. Prior fibrinolysis;~4. Unstable clinical status (hemodynamic or electrical instability);~5. Planned surgery requiring DAPT discontinuation during the study;~6. Prior stroke, transient ischemic attack or intracranial bleeding;~7. Active bleeding;~8. Severe anemia (hemoglobin \< 8g/dL);~9. Platelet count ≤80x103/ml;~10. Renal failure (hemodialysis or creatinine clearance ≤ 30 ml/min calculated with Cockroft-Gault formula);~11. Severe hepatic dysfunction (baseline alanine aminotransferase ≥ 2.5 times the upper limit of normal);~12. Known hypersensitivity or contraindication to ticagrelor;~13. Under judicial protection, tutorship or curatorship;~14. Unable to understand and follow study-related instructions;~15. Enrollment in another investigational device or drug study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose of ticagrelor (90 mg twice daily). (Type: EXPERIMENTAL): Standard dose of ticagrelor (90 mg twice daily) followed by lower dose of ticagrelor (60 mg twice daily).
- Low dose of ticagrelor (60 mg twice daily). (Type: EXPERIMENTAL): Low dose of ticagrelor (60 mg twice daily) followed by standard dose of ticagrelor (90 mg twice daily).

Based on this trial design, predict the completion outcome and termination type (if applicable).